MDACC Study No:2010-0776 ( NCT No: NCT01309789 )
Title:A Phase 1 Study of Brentuximab Vedotin Administered
Sequentially and Concurrently with Multi-Agent Chemotherapy
as Front-Line Treatment in Patients with CD30-Positive Mature
T-Cell and NK-Cell Neoplasms, Including Systemic Anaplastic
Large Cell Lymphoma
Principal Investigator:Michelle A. Fanale
Treatment Agent:Cyclophosphamide; Doxorubicin; Prednisone; SGN-35; Vincristine
Study Status:Closed
Study Description:The goal of this clinical research study is to learn about the safety and
effectiveness of brentuximab vedotin given before and after standard
chemotherapy called CHOP (cyclophosphamide, doxorubicin, vincristine, and
prednisone) and brentuximab vedotin given with and after a chemotherapy called
CH-P (cyclophosphamide, doxorubicin, and prednisone) in patients with ALCL.

Researchers also want to learn the highest tolerable dose of brentuximab
vedotin that can be given in combination with CH-P chemotherapy.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I
Treatment Agents:Cyclophosphamide
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Seattle Genetics, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
For Clinical Trial Enrollment:713-792-2806
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults